Cullinan Therapeutics, Inc.
CGEM
$13.13
-$0.31-2.31%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.31M | 13.63M | 14.77M | 13.54M | 14.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.26M | 55.60M | 75.80M | 55.00M | 55.05M |
| Operating Income | -55.26M | -55.60M | -75.80M | -55.00M | -55.05M |
| Income Before Tax | -50.71M | -50.61M | -70.06M | -48.50M | -47.53M |
| Income Tax Expenses | -- | -- | -- | -- | 117.00K |
| Earnings from Continuing Operations | -50.71M | -50.61M | -70.06M | -48.50M | -47.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | 0.00 |
| Net Income | -50.71M | -50.61M | -70.06M | -48.50M | -47.65M |
| EBIT | -55.26M | -55.60M | -75.80M | -55.00M | -55.05M |
| EBITDA | -55.18M | -55.52M | -75.72M | -54.92M | -54.97M |
| EPS Basic | -0.86 | -0.86 | -1.19 | -0.82 | -0.81 |
| Normalized Basic EPS | -0.54 | -0.54 | -0.74 | -0.51 | -0.51 |
| EPS Diluted | -0.86 | -0.86 | -1.19 | -0.82 | -0.81 |
| Normalized Diluted EPS | -0.54 | -0.54 | -0.74 | -0.51 | -0.51 |
| Average Basic Shares Outstanding | -- | 59.08M | 59.02M | 58.91M | 58.58M |
| Average Diluted Shares Outstanding | 59.08M | 59.08M | 59.02M | 58.91M | 58.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |